 Part B is a multiple dose, open-label study design to determine the PK, PD, safety and tolerability of multiple doses in subjects with ESRD who require hemodialysis with refractory uremic pruritus UP. Each subject will receive 3 doses of TRK-820 2.5, 5 and 10 μg. 